About 1,564,295 results

Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management

Jun 1st, 2020 - Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).

PyL PET Tracer May Be Superior to Standard Imaging for Prostate Cancer

May 30th, 2020 - PSMA-targeted 18F-DCFPyL-PET/CT imaging demonstrated excellent diagnostic performance in men with biochemically relapsed prostate cancer in terms of a correct localization rate that far exceeded the criteria to meet the primary end point, according to findings from the phase 3 CONDOR trial.

Diagnostic Performance of PSMA-Targeted PET Tracer Excels in Relapsed Prostate Cancer

May 30th, 2020 - Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer in the phase 3 CONDOR trial.

PSMA-Targeted PET Tracer Outperforms Standard Diagnostic Modalities in Relapsed Prostate Cancer

May 30th, 2020 - 18F-DCFPyL-PET/CT imaging outperfomed standard imaging modalities, including bone scan, CT, MRI, and FDG PET, in patients with biochemically relapsed prostate cancer, according to the phase 3 CONDOR study.

18F-DCFPyL–PET/CT Imaging Improves Diagnostic Capability in Relapsed Prostate Cancer

May 29th, 2020 - Imaging with 18F-DCFPyL–PET/CT was found to be diagnostically effective, often guiding a change in treatment plan, in men with biochemically relapsed prostate cancer, according to the results of the phase III CONDOR study presented during the ASCO20 Virtual Scientific Program (Abstract 5501).

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care.

Improved Treatment Response Following Magnetic Resonance Imaging–Guided Focused Ultrasound for Lumbar Facet Joint Pain

Magnetic resonance imaging–guided focused ultrasound (MRgFUS) is a noninvasive modality that allows for precise tissue ablation with sparing of surrounding structures. Early reports of the use of MRgFUS for the treatment of facet joint osteoarthritis are promising. We present a case of facet joint pain treated successfully by MRgFUS at our institution. Magnetic resonance imaging–guided focused ...

Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection

Myocarditis is a significant cause of sudden cardiac death in competitive athletes and can occur with normal ventricular function.1 Recent studies have raised concerns of myocardial inflammation after recovery from coronavirus disease 2019 (COVID-19), even in asymptomatic or mildly symptomatic patients.2 Our objective was to investigate the use of cardiac magnetic resonance (CMR) imaging in com...

Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia

Levodopa-induced dyskinesia (LID) is the most common, disruptive complication of Parkinson’s disease (PD) pharmacotherapy, yet despite decades of research, the changes in regional brain function underlying LID remain largely unknown. We previously found that the cerebral vasomotor and metabolic responses to levodopa are dissociated in PD subjects. Nonetheless, it is unclear whether levodopa-med...

The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies

The purpose of review is to review the current status of positron emission tomography (PET) molecular imaging of serotonergic system in Parkinson’s patients who experience levodopa-induced (LIDs) and graft-induced dyskinesias (GIDs). PET imaging studies have shown that Parkinson’s disease is characterized by progressive loss of dopaminergic and serotonergic neurons. Parkinson’s patients who exp...

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
NPJ Parkinson's Disease;

Levodopa-induced dyskinesias (LID) negatively impact on the quality of life of patients with Parkinson’s disease (PD). We assessed the risk factors for LID in a cohort of de-novo PD patients enrolled in the Parkinson’s Progression Markers Initiative (PPMI). This retrospective cohort study included all PD patients enrolled in the PPMI cohort. Main outcome was the incidence rate of dyskinesia, de...

Imaging in Parkinson’s disease
Clinical Medicine;

The clinical presentation of Parkinson’s disease (PD) is heterogeneous and overlaps with other conditions, including the parkinsonian variant of multiple system atrophy (MSA-P), progressive supranuclear palsy (PSP) and essential tremor. Imaging of the brain in patients with parkinsonism has the ability to increase the accuracy of differential diagnosis. Magnetic resonance imaging (MRI), single ...

Dopamine Transporter Density in de novo Parkinson's Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias

In Parkinson’s disease (PD), the onset of levodopa-induced dyskinesias (LIDs) is difficult to predict. This study examines whether dopamine transporter (DAT)-specific SPECT imaging in de novo PD relates to later development of LIDs.

Alcohol Intoxication and Cognition: Implications on Mechanisms and Therapeutic Strategies

Binge alcohol drinking is highly prevalent in young adults and results in 30% deaths per year in young males. Binge alcohol drinking or acute alcohol intoxication is a risk factor for developing alcohol use disorder (AUD). Three FDA approved drugs are currently in use as therapy for AUD; however, all of them have contra-indications and limitations. Structural brain imaging studies in alcoholics...

Air Pollution May Neutralize Brain Benefits From Exercise
Medscape Greb E.

Dec 21st, 2021 - Vigorous physical activity may exacerbate the association between air pollution and changes in the brain, while air pollution itself can attenuate the benefits of exercise, new imaging research suggests. Results from an epidemiologic cohort study showed the association between nitrogen dioxide (NO2) and white matter hyperintensity volume (WMHV) was stronger in participants who had 30 or more...

Highlighting COVID-19 Blood Clot Dangers

Based on recent reports that demonstrated a strong association between elevated D-dimer levels and poor prognosis, concerns have risen about thrombotic complications in patients with COVID-19. To address these concerns, the National Institute for Public Health of the Netherlands asked a group of radiology and vascular medicine experts to provide guidance for the imaging workup and treatment of ...

Optics shine a light on dental imaging
Nature Savage N.

Oct 27th, 2021 - One day soon, a person might be able to find cavities long before they appear on a dental X-ray, and early enough that the decay can be stopped in its tracks. All it would take is an instrument similar to an electric toothbrush that is fitted with a camera and an LED instead of a brush. You would rinse with a special mouthwash, run the instrument over your teeth, then look at your smartphone to...

Brain imaging before and after COVID-19 in UK Biobank
Medrxiv Douaud G, Lee S et. al.

Jun 14th, 2021 - There is strong evidence for brain-related pathologies in COVID-19, some of which could be a consequence of viral neurotropism. The vast majority of brain imaging studies so far have focused on qualitative, gross pathology of moderate to severe cases, often carried out on hospitalised patients.

Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in...
https://doi.org/10.1007/s12149-021-01694-5 10.1016/j.mayocp.2019.01.013 10.1016/j.mayocp.2019.01.034 10.1200/JCO.2005.04.4859 10.1056/NEJMoa1504627 10.1056/NEJMoa1507643 10.1016/j.cllc.2020.02.017 10.1056/NEJMoa1501824 10.1056/NEJMoa1606774 10.1016/S0140-6736(18)32409-7 10.1097/JTO.0000000000000678 10.21037/qims.2018.08.02 10.1080/2162402X.2019.1580128 10.1002/cncr.22049 10.1186/s12885-020-6582-4 10.1002/jcp.26609 10.1001/jamaoncol.2017.4771 10.2967/jnumed.108.057307 10.1186/s13550-019-0473-1 10.3390/cancers12020371 10.1007/s13139-014-0280-6 10.1371/journal.pone.0225959 10.1007/s00259-014-2903-7 10.1007/s00259-019-04615-x 10.1016/j.ejca.2016.03.012 10.1007/s12149-018-1309-1 10.1016/j.prp.2015.10.006 10.1016/S0169-5002(02)00172-1 10.1016/j.ejrad.2014.12.009 10.2214/AJR.12.9795 10.1097/MNM.0b013e32835fe1f4 10.3390/cancers12082234 10.1016/j.radonc.2017.06.004 10.1007/s00259-019-04348-x 10.1111/crj.12391
Annals of Nuclear Medicine; Eude F, Guisier F et. al.

Jan 22nd, 2022 - Metabolic tumour volume (MTV) measured on fluorodeoxyglucose F18 (FDG) positron emission tomography coupled with computed tomography (PET/CT) is a prognostic factor of advanced non-small cell lung cancer (NSCLC) treated by first-line immunotherapy. However, these tumours are often necrotic and the necrosis, which is hypometabolic in PET FDG, is not included in the MTV. The aim of this study was...

Multiple Cerebral Cavernous Malformations - Clinical Course of Confirmed, Assumed and N...
European Journal of Neurology; Santos AN, Rauschenbach L et. al.

Jan 22nd, 2022 - Analyze and compare the natural course of confirmed familial cerebral cavernous malformation (FCCM), assumed FCCM and non-familial multiple cerebral cavernous malformation (CCM) disease over a 5-year period. Our institutional database was screened for patients with CCM admitted between 2003 and 2020. Patients with complete magnetic resonance imaging dataset, evidence of multiple CCM, clinical b...